Uplizd · Biologic Formulation Platform.

Uplizd's Accelerated Formulation Design service is built on a simple premise: a biologics team should not have to spend two to three development quarters, or longer, and grams of precious drug substance to discover which excipient system its molecule actually wants. Starting from nothing more than a primary sequence and a set of product targets (concentration, presentation, device and the constraints the program already carries), Uplizd delivers a rank-ordered, fully specified set of formulation candidates and the bench-level standard operating procedures needed to make them, typically within two weeks. Formulation development becomes a focused confirmatory exercise instead of an open-ended empirical search. The work is done by a coordinated set of specialist AI agents, with an orchestrator routing between them and a validation gate governing what they are allowed to conclude: Understand the molecule: Sequence Analysis turns a primary sequence into a formulation-relevant profile with liability reports; Literature Data retrieves structure–function evidence from publications, patents and your own knowledge base. Ground it in precedent: Regulatory Information retrieves precedent from inactive-ingredient databases, drug labels and published formulations; Regulatory Validation gates the design before and after it is made. Design the formulation: Excipient Selection builds a complete excipient system; the Compounding Calculator converts it into an exact, error-checked recipe; the High-Concentration Specialist addresses self-association, opalescence and phase separation. Plan and read the experiments: DoE Planning maps the design space with factorial, Plackett–Burman, Box–Behnken, central composite and D-optimal designs; the Stability Specialist interprets returned data and ranks candidates with a failure mechanism attached to each. Write it down: Documentation generates formulation rationale, excipient justification and stability reports, each section carrying provenance and hyperlinked citations. Agents run in waves rather than a queue: independent work happens in parallel, and each wave begins only once the evidence it depends on exists. The value is greatest at high concentration. Subcutaneous and autoinjector presentations increasingly need 100–250 mg/mL of protein in 1–2 mL, where protein–protein interactions dominate and self-association, aggregation, chemical degradation, viscosity and manufacturability all become sensitive at once. Designing for that regime up front pulls in the timing of tox lots, stability starts, first-in-human enabling material and, eventually, the CMC sections of regulatory filings. Uplizd is offered two ways. In the service engagement, our scientists run the system on your molecule; every outcome vests in you and your materials are destroyed at close-out. In the platform engagement, we customize the same system to your molecules, rules and SOPs, deploy it in your cloud or on premises on any leading model, and hand over the complete source code, build and deployment artefacts, infrastructure-as-code and documentation.